Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics

SANTA CLARA, Calif.–(Business enterprise WIRE)–Agilent Systems Inc. (NYSE: A) today declared it is investing approximately $725 million to double producing potential of therapeutic nucleic acids in response to swift advancement of the $1 billion industry and powerful desire for the company’s superior-excellent energetic pharmaceutical components (API).

Therapeutic nucleic acids, also named therapeutic oligonucleotides or oligos, are brief DNA and RNA molecules that provide as the API for medicine concentrating on a escalating quantity of conditions, which include most cancers, cardiovascular disorder, and exceptional and infectious ailments.

“This investment reflects not only the strong demand for therapeutic oligos, but also for the unmatched top quality and assistance of our therapeutic oligo agreement improvement and production firm (CDMO),” reported Mike McMullen, Agilent president and CEO. “It’s nevertheless yet another instance of our focus on investing in significant-advancement marketplaces whilst also delivering on Agilent’s mission of bettering the excellent of existence.”

The industry for therapeutic oligos is at present believed at $1 billion and is projected to expand in the double digits each year about the following 5 decades, reaching $2.4 billion in 2027. The addition of two new production lines (identified as Trains C and D) will enable Agilent to meet up with growing desire for siRNA, antisense and CRISPR tutorial RNA molecules. Agilent expects purchaser shipments from the expansion to begin in 2026.

“One of our strategic priorities is to support current and new biopharma customers create, globally commercialize, and accelerate growth of oligo-primarily based therapeutics,” mentioned Sam Raha, president of Agilent’s Diagnostics and Genomics Group. “This more ability will enable us to fulfill solid desire for siRNA and antisense molecules and also noticeably improve the amount of CRISPR manual RNA applications we can acquire on.”

The new Practice C and D producing lines will be based mostly in Agilent’s Frederick, Colorado facility, the place a Educate B production line, announced in 2020, will go are living later this yr.

Agilent’s therapeutic oligo amenities observe existing superior producing tactics (cGMP), and the expanded facility will make use of sophisticated automation and engineering enhancements, which includes water reduction and solvent capturing and recycling. Read additional about Agilent’s oligo API development and production services and history on oligos for therapeutics in Agilent’s media room.

About Agilent Systems

Agilent Systems Inc. (NYSE: A) is a world wide leader in the everyday living sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the excellent of daily life. Agilent’s whole selection of answers involves devices, software package, providers, and skills that supply dependable solutions to our customers’ most tough queries. The firm produced income of $6.85 billion in fiscal 2022 and employs 18,000 individuals all over the world. Info about Agilent is out there at www.agilent.com. To acquire the most up-to-date Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Ahead On the lookout Statements

This information launch consists of ahead-searching statements as described in the Securities Exchange Act of 1934 and is subject matter to the risk-free harbors designed therein. The forward-looking statements contained herein consist of, but are not minimal to, statements about the abilities the producing capability growth brings and the assets’ upcoming makes use of. These forward-hunting statements include risks and uncertainties that could induce Agilent’s benefits to differ materially from management’s latest anticipations. This sort of challenges and uncertainties include things like, but are not constrained to, unexpected adjustments in the toughness of Agilent’s customers’ businesses unexpected variations in the need for current and new goods, technologies, and solutions unexpected alterations in the forex marketplaces and client buying selections and timing. In addition, other hazards that Agilent faces in running its operations consist of the means to execute productively via small business cycles the potential to satisfy and realize the added benefits of its price-reduction targets and in any other case successfully adapt its value buildings to continuing variations in organization circumstances ongoing competitive, pricing and gross-margin pressures the threat that its price tag-chopping initiatives will impair its ability to create products and solutions and stay competitive and to operate successfully the effects of geopolitical uncertainties and international economic problems on its functions, its markets and its potential to conduct business the skill to make improvements to asset performance to adapt to modifications in need the capacity of its source chain to adapt to adjustments in demand from customers the potential to efficiently introduce new products and solutions at the right time, value and mix the skill of Agilent to correctly combine current acquisitions the capability of Agilent to correctly comply with certain complex rules the adverse impacts of and risks posed by the COVID-19 pandemic and other hazards thorough in Agilent’s filings with the Securities and Exchange Commission, including its yearly report on Kind 10-K for the fiscal quarter ended Oct 31, 2022. Forward-hunting statements are primarily based on the beliefs and assumptions of Agilent’s administration and on presently obtainable data. Agilent undertakes no obligation to publicly update or revise any ahead-looking assertion.